The global market for pooled CRISPR screening is poised for substantial growth, driven by advancements in functional genomics research, pharmaceutical R&D, and gene-editing technologies. According to a recent report by ResearchAndMarkets.com, the market is projected to expand from $1.3 billion in 2025 to $1.51 billion in 2026, marking a compound annual growth rate (CAGR) of 15.9%.
By 2030, the market is expected to reach $2.74 billion, with a CAGR of 16.1%. This growth trajectory is underpinned by the integration of artificial intelligence in gene screening, the adoption of cloud-based genomics platforms, and the increasing application of personalized medicine. Additionally, advances in high-throughput screening workflows and the expansion of biotechnology infrastructure are contributing to this robust growth.
Key trends in the market include the integration of multi-omics data, automation of CRISPR processes, AI-driven gene target identification, and real-time functional genomics analysis. The rising prevalence of genetic disorders, coupled with improved diagnostic capabilities and broader access to genetic screening, is also playing a significant role in market expansion. For instance, the Cystic Fibrosis Trust reported an increase in registered cystic fibrosis patients in the UK from 11,148 in 2022 to 11,318 in 2023, a growth of approximately 1.5% year-over-year1.
Innovations in transcriptome-wide profiling are enhancing the market by enabling high-throughput functional genomics and precise therapeutic target identification. In June 2023, Parse Biosciences Inc. launched CRISPR Detect, a technology designed for large-scale, single-cell pooled CRISPR screening. This technology integrates with their Evercode Whole Transcriptome platform, allowing for comprehensive gene perturbation studies across up to one million cells per experiment2. This approach addresses throughput and cost limitations associated with traditional droplet-based single-cell RNA sequencing, expanding opportunities in genome-scale gene function analysis, regulatory network mapping, signaling pathway research, and drug discovery.
Investment in research and development is accelerating the adoption of pooled CRISPR screening technologies. Increased funding allows for the enhancement of gene-editing tools, optimization of experimental protocols, and improvement of screening accuracy. The UK Office for National Statistics reported an 8.2% increase in government net spending on R&D, from £16.1 billion ($20.45 billion) in 2022 to £17.4 billion ($22.1 billion) in 20233. This trend of rising public and private investment is expected to support the wider deployment of advanced CRISPR screening platforms.
The market comprises various segments, including genome-wide and targeted screening solutions, libraries, reagents and kits, instruments, software, and services. Core technologies involve CRISPR-Cas9 screening, CRISPR interference screening, and CRISPR activation screening. Applications span functional genomics, drug discovery, cancer research, and gene regulation. Demand primarily comes from pharmaceutical and biotechnology companies, academic and research institutions, and contract research organizations seeking scalable tools for disease modeling and therapeutic development.
Regionally, North America was the largest market for pooled CRISPR screening in 2025, supported by a robust biotechnology infrastructure and substantial research funding. The Asia-Pacific region is anticipated to be the fastest-growing market during the forecast period, driven by increased investment in biotechnology, pharmaceutical research, and precision medicine. The market analysis covers regions such as Asia-Pacific, Western and Eastern Europe, North America, South America, the Middle East, and Africa, with countries like the USA, China, India, and Germany being key players.
The report also highlights the competitive landscape, featuring companies such as Thermo Fisher Scientific Inc., Merck KGaA, Danaher Corporation, Agilent Technologies Inc., and QIAGEN N.V., among others. These companies are at the forefront of innovation, driving the market with new products and technologies. Their efforts in advancing CRISPR technologies are crucial for the market’s sustained growth and the development of new therapeutic solutions.
Footnotes:
- The number of registered cystic fibrosis patients in the UK increased from 11,148 in 2022 to 11,318 in 2023. Source.
- Parse Biosciences Inc. launched CRISPR Detect in June 2023 for large-scale, single-cell pooled CRISPR screening. Source.
- UK government net spending on R&D rose by 8.2% from 2022 to 2023. Source.
Featured Image: DepositPhotos @ DimaBaranow